CRISPR Therapeutics AG CRSP

The Motley Fool 13 nov

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

GlobeNewswire Inc. 8 nov

CRISPR Therapeutics reported encouraging Phase 1 clinical data for zugo-cel, its allogeneic CAR-T cell therapy, across multiple autoimmune disease indications. In systemic sclerosis, 83% of patients achieved clinical response at Month 3 with maintained responses through Month 6+. All nine idiopathic inflammatory myopathy patients showed moderate to major improvement. The therapy demonstrated a favorable safety profile with no serious adverse events reported across 21 dosed patients. Dose escalation studies are ongoing with higher CAR-T cell expansion observed at increased dose levels.

The Motley Fool 7 nov

The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.

Zacks Investment Research 6 nov

CRISPR Therapeutics (CRSP) is receiving increased investor attention. The stock has underperformed the S&P 500 over the past month (-3.7% vs -5.4%). While the company shows strong revenue growth projections (+771.8% for current fiscal year), it carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (F grade). The company is expected to turn profitable next fiscal year with projected EPS of $3.73.

Zacks Investment Research 2 nov

CRISPR Therapeutics (CRSP) reported a quarterly loss of $1.15 per share, missing consensus estimates of $1.06 loss by 8.49%, though revenues of $12.67 million exceeded expectations by 27.39%. The stock has underperformed the S&P 500 by 12.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.